Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-500-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology Inc (NASDAQ:KURA) announced its quarterly earnings data on Thursday, August, 1st. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.03. View Kura Oncology's Earnings History.
When is Kura Oncology's next earnings date?
What price target have analysts set for KURA?
9 equities research analysts have issued 1 year target prices for Kura Oncology's stock. Their forecasts range from $22.00 to $32.00. On average, they anticipate Kura Oncology's stock price to reach $27.25 in the next twelve months. This suggests a possible upside of 66.5% from the stock's current price. View Analyst Price Targets for Kura Oncology.
What is the consensus analysts' recommendation for Kura Oncology?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (9/17/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and are adjusting our price target to $29 from $31 based on the following factors: (1) adjustment to base year (positive effect); and (2) adjustment to fully diluted share count, taking into account the recent equity financing. The primary contributor to our valuation is tipifarninb (93.9%). Of tipifarnib’s contribution, 46.7% comes from the lead opportunity in HNSCC, with the remainder coming from the other indications currently being pursued (i.e., and CMML)." (8/2/2019)
Has Kura Oncology been receiving favorable news coverage?
News articles about KURA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kura Oncology earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Kura Oncology.
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), HUTCHISON CHINA/S (HCM), Genmab A/S (GMAB), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO) and Portola Pharmaceuticals (PTLA).
What other stocks do shareholders of Kura Oncology own?
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
- Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
- Dr. Marc Grasso, CFO & Chief Bus. Officer
- Mr. John Farnam, Chief Operating Officer
- Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
Who are Kura Oncology's major shareholders?
Kura Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.32%), Eagle Asset Management Inc. (5.35%), Vanguard Group Inc. (4.45%), Victory Capital Management Inc. (4.35%), Arch Venture Corp (3.00%) and Brown Advisory Inc. (1.33%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View Institutional Ownership Trends for Kura Oncology.
Which major investors are selling Kura Oncology stock?
KURA stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Capital Impact Advisors LLC, Candriam Luxembourg S.C.A., Alps Advisors Inc., Tiverton Asset Management LLC, Susquehanna International Group LLP, Virtus ETF Advisers LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for Kura Oncology.
Which major investors are buying Kura Oncology stock?
KURA stock was bought by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Vanguard Group Inc., Marshall Wace LLP, Citadel Advisors LLC, Monashee Investment Management LLC, Victory Capital Management Inc., Man Group plc and Nuveen Asset Management LLC. View Insider Buying and Selling for Kura Oncology.
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $16.37.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $740.25 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.
What is Kura Oncology's official website?
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
